A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma.

Area of Science:

• Oncology
• Cancer Biology
• Molecular Medicine

Background:

• Glioblastoma (GBM) therapy resistance and progression are linked to intra-tumor heterogeneity.
• Identifying and targeting therapy-resistant tumor cell populations is crucial for improving patient outcomes.

Purpose of the Study:

• To identify molecular markers of glioblastoma cells that survive and adapt under therapy.
• To understand the dynamics of subclonal progression in response to treatment.
• To develop novel therapeutic strategies targeting adaptive resistance mechanisms.

Main Methods:

• Analysis of paired tumor samples from patients before and after therapy.
• Validation using independent clinical cohorts and patient-derived xenograft models.
• Investigation of ALDH1A1 expression and AKT signaling pathways.

Main Results:

• Rare ALDH1A1+ tumor cells enrich and acquire AKT-mediated resistance after temozolomide (TMZ) treatment.
• Drug resistance in ALDH1A1+ cells is an adaptive mechanism, not intrinsic.
• Sequential combination therapy targeting TMZ and AKT signaling effectively interfered with subclonal progression in preclinical models.

Conclusions:

• Drug-resistant ALDH1A1+/pAKT+ subclones accumulate in glioblastoma tissues following TMZ adaptation.
• These adaptive subclones represent a dynamic therapeutic target.
• Sequential administration of TMZ and AKT inhibitors is a promising strategy for future clinical trials in glioblastoma.